U.K. pulls 5 Rx drugs from India's Wockhardt

The U.K. Medicines and Healthcare Products Regulatory Agency on Thursday recalled five prescription drugs, including the diabetes drug Gliclazide, from India's Wockhardt after discovering manufacturing deficiencies at the company's facility in India. "There is no evidence that the medicines affected by the precautionary recall in the U.K. are defective," the agency said. Wockhardt will still be allowed to continue its exports of 10 prescription medicines because not all drug imports have been banned from the facility, the agency said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA